Deepverge PLC - Trading Update & Investor Presentation

1 December 2020

DeepVerge PLC

("DeepVerge" or "the Company")

Trading Update & Investor Presentation

DeepVerge (LSE:DVRG.L), the scientific research and AI-as-a-Service company, is pleased to announce that guidance of £4m revenues for the Company for year ending 31 December 2020 remains on track  and amalgamated revenues which include Modern Water plc, acquired on 9 November, 2020, are expected to be well above £4m.

Gerry Brandon, Chief Executive Officer, will be presenting at an investor webinar being hosted jointly by Turner Pope Investments (TPI) Ltd and Vox Markets.

The event will be held later today, 1 December 2020 at 2pm. Please register your interest at  https://voxmarkets.brand.live/c/deepverge-webinar

A copy of the webinar presentation will be posted on the DeepVerge website contemporaneously.

Gerard Brandon, CEO of DeepVerge, Commented:

"The presentation will reiterate the guidance for 2020, provide an update on sales, marketing, supply chain management of products and services under development for a post-COVID world and I look forward to the opportunities that are ahead for the enlarged Group."

For further information please contact:

About DeepVerge plc (www.deepverge.com)

DeepVerge is a scientific research and AI-as-a-Service company focused on production and analysis of bacteria, virus and toxins utilising artificial intelligent data analytics in regulatory technology, from scientifically proving the impact of skincare product claims on skin microbiome for top 20 global cosmetic company clients to remotely detecting water contamination in real-time.

In November 2020, DeepVerge acquired Modern Water who developed and commercialised a cutting-edge technology, focused on monitoring of contaminated water and decontamination of wastewater, making recycling of water more efficient. Six countries across the world have legislated that Modern Water monitoring test systems are written into their environmental protection legislation.  The Company is in final trials for its real-time contamination product, Microtox PD, for the identification of COVID-19 hotspots and other pathogens.